Narcolepsy is a chronic neurological sleep disorder characterized by excessive daytime sleepiness and dysregulation of rapid eye movement (REM) sleep. Type 1 narcolepsy results from selective loss of hypothalamic orexin/hypocretin-producing neurons, presumed autoimmune in origin, and presents with cataplexy; type 2 lacks cataplexy and preserves orexin levels. Associated features include sleep paralysis, hypnagogic hallucinations, and fragmented nocturnal sleep.
Ask a research question about Narcolepsy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Narcolepsy
creation_date: '2025-12-19T14:27:56Z'
description: >-
Narcolepsy is a chronic neurological sleep disorder characterized by excessive
daytime sleepiness and dysregulation of rapid eye movement (REM) sleep. Type 1
narcolepsy results from selective loss of hypothalamic
orexin/hypocretin-producing neurons, presumed autoimmune in origin, and presents with cataplexy;
type 2 lacks cataplexy and preserves orexin levels. Associated features include
sleep paralysis, hypnagogic hallucinations, and fragmented nocturnal sleep.
category: Neurological Disorder
parents:
- Sleep Disorder
- Neurological Disease
disease_term:
preferred_term: narcolepsy
term:
id: MONDO:0021107
label: narcolepsy
has_subtypes:
- name: Narcolepsy Type 1
description: With cataplexy and orexin/hypocretin deficiency.
evidence:
- reference: DOI:10.1111/jsr.14277
reference_title: Narcolepsy and rapid eye movement sleep
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >
The disease is nowadays distinguished as narcolepsy type 1 and type 2.
explanation: >
The deep-research report surfaced this 2024 review as current support for
the NT1/NT2 subtype split.
- name: Narcolepsy Type 2
description: Without cataplexy, normal or near-normal orexin levels.
evidence:
- reference: DOI:10.1111/jsr.14277
reference_title: Narcolepsy and rapid eye movement sleep
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >
Conversely, the causes of narcolepsy type 2, where cataplexy and orexin
deficiency are absent, remain unknown.
explanation: >
This directly supports the NT2 definition used in the subtype assertion.
pathophysiology:
- name: Orexin/Hypocretin Deficiency
description: >
Loss of orexin-producing neurons in the lateral hypothalamus removes the
signal that normally holds the sleep-wake switch in a stable position.
Postmortem series show an 85-95% reduction in orexin neuron number, and the
loss is cell-type-selective: the intermingled melanin-concentrating hormone
neurons are spared, which excludes a nonspecific hypothalamic lesion. Because
the population is small and unreplaced, the deficit is permanent, and it is
detectable in life as low or undetectable CSF hypocretin-1.
Scoped to Narcolepsy Type 1: CSF hypocretin-1 is normal or intermediate in
most patients with Type 2, which is why this node - and its conformance to
the orexin module's trigger - applies to the Type 1 subtype only.
role: trigger
biological_scale: CELLULAR
subtypes:
- Narcolepsy Type 1
conforms_to: "orexin_arousal_instability#Loss of Hypothalamic Orexin (Hypocretin) Signal"
downstream:
- target: Sleep-Wake State Instability
description: >-
Loss of the orexin signal removes excitatory drive to the ascending arousal
nuclei, so the sleep-wake switch can no longer be held stable and flips at
inappropriate times in both directions.
causal_link_type: DIRECT
cell_types:
- preferred_term: Orexin Neuron
term:
id: CL:0011109
label: hypocretin-secreting neuron
biological_processes:
- preferred_term: Sleep-Wake Regulation
term:
id: GO:0042745
label: circadian sleep/wake cycle
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: OTHER
snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
explanation: Landmark review establishes hypocretin neuron loss as the cause of narcolepsy with cataplexy.
- name: Autoimmune Destruction
description: >
Strong HLA-DQB1*06:02 association suggests autoimmune etiology. T-cell
mediated destruction of hypocretin neurons is the leading hypothesis.
Environmental triggers (infections, H1N1 vaccination) may initiate
the autoimmune response in genetically susceptible individuals. Direct
cellular evidence has since been obtained: hypocretin-specific CD4+ T cells
are detectable in patients and not in controls, and hypocretin-specific CD8+
T cells are found in blood and cerebrospinal fluid.
role: trigger
biological_scale: CELLULAR
subtypes:
- Narcolepsy Type 1
downstream:
- target: Orexin/Hypocretin Deficiency
description: >-
Immune-mediated destruction of the orexin-producing neurons is the route by
which the orexin signal is lost in Type 1 narcolepsy.
causal_link_type: DIRECT
biological_processes:
- preferred_term: Autoimmune Response
term:
id: GO:0002460
label: adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: OTHER
snippet: "The hypothesis that a targeted immune-mediated or autoimmune attack causes the specific degeneration of hypocretin neurons arose mainly through the discovery of genetic associations, first with the HLA-DQB1*06:02 allele and then with the T-cell receptor α locus."
explanation: Genetic associations with HLA and TCR loci strongly support autoimmune etiology.
- reference: PMID:32227223
reference_title: "Narcolepsy type 1: what have we learned from immunology?"
supports: SUPPORT
snippet: "Narcolepsy type 1 is hypothesized to be an autoimmune disease targeting the hypocretin/orexin neurons in the hypothalamus. Ample genetic and epidemiological evidence points in the direction of a pathogenesis involving the immune system"
explanation: Recent review summarizing that genetic and epidemiological evidence supports autoimmune pathogenesis.
- reference: PMID:38077397
reference_title: "The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I."
supports: SUPPORT
snippet: "Narcolepsy Type I (NT1) is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons. The mechanisms involved in the destruction of orexin neurons are not yet elucidated but the association of narcolepsy with environmental triggers and genetic susceptibility (strong association with the HLA, TCRs and other immunologically-relevant loci) implicates an immuno-pathological process."
explanation: Transcriptomic study confirms the immunological basis and T-cell involvement in narcolepsy pathogenesis.
- name: Sleep-Wake State Instability
description: >-
The rate-limiting step, and the node that makes sense of the disorder's
apparent paradox. Loss of orexinergic stabilisation does not abolish any
single behavioural state; it makes every state transition too easy.
Wakefulness fragments into involuntary sleep episodes, and nocturnal sleep
fragments into frequent awakenings - which is why these patients are
simultaneously excessively sleepy by day and poor sleepers by night, an
observation a simple "insufficient wake drive" account does not predict.
Unlike the trigger nodes above, this node is not scoped to Type 1: Type 2
patients show the same state instability without a demonstrated orexin
deficit, which is precisely why the module places its conformance bar at the
trigger rather than here.
role: central_effector
biological_scale: ORGANISM
conforms_to: "orexin_arousal_instability#Sleep-Wake State Instability"
biological_processes:
- preferred_term: sleep-wake cycle state transition
term:
id: GO:0022410
label: circadian sleep/wake cycle process
modifier: ABNORMAL
- preferred_term: regulation of the sleep-wake cycle
term:
id: GO:0042749
label: regulation of circadian sleep/wake cycle
modifier: DECREASED
evidence:
- reference: PMID:10481909
reference_title: "Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
We propose that orexin regulates sleep/wakefulness states
explanation: >-
Names the function lost at this node - regulation of behavioural state
rather than production of wakefulness - which is the distinction that makes
the day-night paradox coherent.
- reference: PMID:10458611
reference_title: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
It is characterized by daytime sleepiness, cataplexy, and striking
transitions from wakefulness into rapid eye movement (REM) sleep.
explanation: >-
Describes the instability phenotype as abrupt inappropriate state
transitions, which is the readout this node encodes.
- reference: PMID:11055430
reference_title: Reduced number of hypocretin neurons in human narcolepsy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
human narcoleptics have an 85%-95% reduction in the number of Hcrt neurons
explanation: >-
Human evidence that the lesion upstream of this node is present, and near
total, in patients rather than only in the animal models above - which
matters because this is the entry's rate-limiting node and the model
evidence alone would not license a human claim.
- reference: PMID:12374492
reference_title: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Narcolepsy-cataplexy with hypocretin deficiency is a genuine disease entity.
explanation: >-
Establishes the hypocretin-deficient state-instability syndrome as a
distinct human entity, not an extrapolation from the knockout phenotype.
downstream:
- target: Dissociated Intrusion of REM Sleep Components
description: >-
An unstable switch permits REM sleep to be entered directly from
wakefulness and permits individual REM components to appear in isolation.
causal_link_type: DIRECT
- name: Dissociated Intrusion of REM Sleep Components
description: >-
REM sleep is normally an all-or-none package: EEG desynchronisation, rapid
eye movements, dreaming, and skeletal muscle atonia arrive together. State
instability lets the package come apart, so single components appear at the
wrong time and without the others. Muscle atonia intruding into full
wakefulness is cataplexy; atonia persisting into waking consciousness at a
state boundary is sleep paralysis; dream imagery without sleep is hypnagogic
hallucination; and the whole state entered directly from wake is a
sleep-onset REM period. This node is what distinguishes orexin-driven
hypersomnolence from every other cause of sleepiness, and is the reason the
multiple sleep latency test counts sleep-onset REM periods rather than only
measuring sleep latency.
role: effector
biological_scale: ORGANISM
conforms_to: "orexin_arousal_instability#Dissociated Intrusion of REM Sleep Components into Wakefulness"
biological_processes:
- preferred_term: REM sleep
term:
id: GO:0042747
label: circadian sleep/wake cycle, REM sleep
modifier: ABNORMAL
notes: >-
The atonia machinery whose intrusion produces cataplexy is the same pontine
circuit modelled in rem_sleep_atonia_control_failure, where it fails in the
opposite direction - atonia absent during REM sleep rather than present
during wakefulness. Narcolepsy type 1 can show both, and REM sleep behaviour
disorder is a recognised association. This entry does not declare conformance
to that module, because it curates no polysomnographic finding of REM sleep
without atonia, which is that module's stated entry requirement.
evidence:
- reference: PMID:10481909
reference_title: "Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
a disorder characterized primarily by rapid eye movement (REM) sleep
dysregulation
explanation: >-
Identifies REM dysregulation as the defining downstream consequence of
orexin loss, which is what this node models.
- reference: PMID:10458611
reference_title: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
This result identifies hypocretins as major sleep-modulating
neurotransmitters
explanation: >-
Places the REM-dissociation phenotype downstream of hypocretin
neurotransmission rather than treating it as an independent finding.
- reference: PMID:12374492
reference_title: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
HLA-DQB1*0602 frequency was increased in narcolepsy with typical cataplexy
(93% vs 17% in controls), narcolepsy without cataplexy (56%), and in
essential hypersomnia (52%).
explanation: >-
Human clinical evidence stratified by the presence of cataplexy - the
REM-dissociation feature this node models - showing that the
cataplexy-positive group is the one carrying the near-complete HLA
association, which grounds the node in patients rather than in the
knockout models above.
- reference: PMID:12374492
reference_title: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These patients did not always have abnormal MSLT.
explanation: >-
Cited as PARTIAL because it qualifies this node in humans: the
sleep-onset-REM readout is not universally present even in
hypocretin-deficient patients, so REM dissociation is characteristic of the
disorder without being obligate on testing.
- reference: PMID:29069490
reference_title: Optimizing MSLT Specificity in Narcolepsy With Cataplexy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A positive MSLT (mean sleep latency ≤ 8.0 minutes and ≥2 SOREMPs) was found
in 53 NC (95%), 1 PD (1%), 8 SDB (9%), and 12 ISS patients (52%).
explanation: >-
The direct human polysomnographic measurement of this node: sleep-onset REM
periods in 95% of narcolepsy-with-cataplexy patients, against 1-9% in the
neurological and respiratory comparators. This is the observation the node
models, measured in patients rather than inferred from the animal models
above.
- reference: PMID:29069490
reference_title: Optimizing MSLT Specificity in Narcolepsy With Cataplexy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Multiple sleep onset rapid eye movement (R) periods (SOREMPs) and a mean
sleep latency of ≤8 minutes on the multiple sleep latency test (MSLT) are
diagnostic criteria of narcolepsy (NC), but also occur in other conditions
with increased sleep pressure, including insufficient sleep syndrome (ISS),
sleep-disordered breathing (SDB), or Parkinson's disease (PD).
explanation: >-
Cited as PARTIAL because it bounds the node's specificity in the quoted
sentence itself: the same readout occurs in other conditions with increased
sleep pressure, so REM dissociation on the MSLT is characteristic of
orexin-deficient narcolepsy without being unique to it - which is why the
module places its conformance bar at the orexin trigger rather than at this
readout. The companion SUPPORT item on this node quantifies the overlap.
phenotypes:
- name: Excessive Daytime Sleepiness
category: Sleep
frequency: OBLIGATE
diagnostic: true
notes: Cardinal symptom, irresistible sleep attacks
evidence:
- reference: PMID:38077397
reference_title: "The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I."
supports: SUPPORT
snippet: "Narcolepsy Type I (NT1) is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons."
explanation: Excessive daytime sleepiness results from loss of orexin neurons that regulate wakefulness.
phenotype_term:
preferred_term: Excessive Daytime Sleepiness
term:
id: HP:0002329
label: Drowsiness
- name: Cataplexy
category: Motor
frequency: VERY_FREQUENT
diagnostic: true
notes: Sudden muscle weakness triggered by emotions, pathognomonic for Type 1
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: OTHER
snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
explanation: Cataplexy is the defining feature that distinguishes Type 1 narcolepsy and is caused by hypocretin deficiency.
phenotype_term:
preferred_term: Cataplexy
term:
id: HP:0002524
label: Cataplexy
- name: Sleep Paralysis
category: Sleep
frequency: FREQUENT
notes: Temporary inability to move upon waking or falling asleep
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: OTHER
snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
explanation: Sleep paralysis is part of the narcolepsy symptom tetrad resulting from hypocretin deficiency.
phenotype_term:
preferred_term: Sleep Paralysis
term:
id: HP:0025233
label: Sleep paralysis
- name: Hypnagogic Hallucinations
category: Psychiatric
frequency: FREQUENT
notes: Vivid dream-like experiences at sleep onset
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: OTHER
snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency"
explanation: Hypnagogic hallucinations are part of the classic narcolepsy tetrad resulting from REM sleep intrusion.
phenotype_term:
preferred_term: Hypnagogic Hallucination
term:
id: HP:0002519
label: Hypnagogic hallucination
- name: Disrupted Nighttime Sleep
category: Sleep
frequency: FREQUENT
notes: Fragmented nocturnal sleep despite daytime sleepiness
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: OTHER
snippet: "Narcolepsy with cataplexy is caused by hypocretin deficiency owing to destruction of most of the hypocretin-producing neurons in the hypothalamus."
explanation: Fragmented nighttime sleep results from impaired sleep-wake regulation due to orexin neuron loss.
phenotype_term:
preferred_term: Sleep Disturbance
term:
id: HP:0002360
label: Sleep disturbance
biochemical:
- name: CSF Orexin/Hypocretin-1
presence: Decreased
context: Low or undetectable in Type 1 narcolepsy (<110 pg/mL)
evidence:
- reference: DOI:10.1111/iji.12688
reference_title: High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >
Narcolepsy is a sleep disorder caused by an apparent degeneration of
orexin/hypocretin neurons in the lateral hypothalamic area and a
subsequent decrease in orexin/hypocretin levels in the cerebrospinal
fluid.
explanation: >
The deep-research report highlighted this 2024 immunogenetics study; its
abstract supports decreased CSF orexin/hypocretin as a key biochemical
marker.
genetic:
- name: HLA-DQB1*06:02
association: Risk Factor
notes: Present in >98% of Type 1 narcolepsy, but also 25% of general population
evidence:
- reference: PMID:32227223
reference_title: "Narcolepsy type 1: what have we learned from immunology?"
supports: SUPPORT
snippet: "Autoreactive T cells and autoantibodies have been detected in blood samples from patients"
explanation: Detection of autoreactive T cells in narcolepsy patients supports the HLA-mediated autoimmune mechanism.
- reference: DOI:10.1111/iji.12688
reference_title: High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >
We confirmed the previous association of NT1 with HLA‐DQB1*06:02:01
extended genotypes.
explanation: >
This deep-research citation updates the HLA assertion with high-resolution
2024 HLA sequencing evidence.
- name: HCRT
gene_term:
preferred_term: HCRT
term:
id: hgnc:4847
label: HCRT
association: Causative
notes: Rare mutations in hypocretin gene cause familial narcolepsy
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."
explanation: Demonstrates that loss of hypocretin gene function causes narcolepsy.
- name: HCRTR2
gene_term:
preferred_term: HCRTR2
term:
id: hgnc:4849
label: HCRTR2
association: Causative
notes: Hypocretin receptor 2 mutations (canine model)
evidence:
- reference: PMID:25728441
reference_title: "Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Ablation of hypocretin or hypocretin receptors also leads to narcolepsy phenotypes in animal models."
explanation: Confirms that hypocretin receptor mutations cause narcolepsy in animal models.
environmental:
- name: H1N1 Infection
exposure_term:
preferred_term: viral exposure
term:
id: ECTO:3000001
label: exposure to virus
notes: Increased risk after 2009 pandemic. Evidenced independently of vaccination
by a Chinese post-pandemic series, in which almost no patient had been vaccinated.
evidence:
- reference: PMID:21866560
reference_title: "Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we found a 3-fold increase in narcolepsy onset following the 2009 H1N1 winter influenza pandemic. The increase is unlikely to be explained by increased vaccination, as only 8 of 142 (5.6%) patients recalled receiving an H1N1 vaccination"
explanation: "Retrospective analysis of onset in 629 Beijing patients, 86 percent of them children. Because vaccination was rare in this sample, it separates the infection exposure from the vaccine exposure curated below."
- name: Pandemrix Vaccine
notes: Associated with increased narcolepsy risk in Europe after the 2009 pandemic
vaccination campaign. The magnitude is drawn from observational studies whose
methodological limitations are contested; both the estimate and the
manufacturer-affiliated critique of it are cited, and they disagree.
evidence:
- reference: PMID:29855798
reference_title: "Narcolepsy Associated with Pandemrix Vaccine."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the risk of narcolepsy was increased 5- to 14-fold in children and adolescents and 2- to 7-fold in adults"
explanation: "Reports the magnitude of the association between the AS03-adjuvanted pandemic vaccine and incident narcolepsy across European studies."
- reference: PMID:26379011
reference_title: "Pandemrix™ and narcolepsy: A critical appraisal of the observational studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "significant methodological limitations of the studies have not been fully addressed and raise questions about the reported risk estimates"
explanation: "Cited deliberately alongside the risk estimate as the dissenting reading of the same twelve European studies. Provenance matters here and is not neutral: the authors are staff and contractors of GSK Vaccines, the manufacturer of Pandemrix, together with a pharmacovigilance consultancy, so this is the manufacturer-affiliated critique rather than independent scrutiny. The two cited sources genuinely disagree - PMID:29855798 concedes that confounding and diagnostic bias may influence some studies but judges it unlikely they explain the increased incidence across every country where Pandemrix was used. The dispute is recorded here rather than resolved."
- name: Streptococcal Infection
exposure_term:
preferred_term: Infectious agent exposure
term:
id: ECTO:3000000
label: exposure to organism
notes: Possible trigger in some cases
evidence:
- reference: PMID:19725248
reference_title: "Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Streptococcal infections are probably a significant environmental trigger for narcolepsy"
explanation: "Serological study of anti-streptolysin O titers in narcolepsy near disease onset. The authors hedge as probable rather than established, which is the level of confidence this note records."
treatments:
- name: Sodium Oxybate
description: First-line for cataplexy and daytime sleepiness, improves nighttime sleep.
evidence:
- reference: PMID:22893778
reference_title: "Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis."
supports: SUPPORT
snippet: "Narcolepsy patients on SXB have significant reductions in cataplexy and daytime sleepiness. SXB is well tolerated in patients with narcolepsy, and most adverse events were mild to moderate in severity."
explanation: Systematic review and meta-analysis of 6 RCTs confirms efficacy for both cataplexy and sleepiness with acceptable safety.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Modafinil
description: Wake-promoting agent for excessive daytime sleepiness.
evidence:
- reference: PMID:20671626
reference_title: "Modafinil for narcolepsy: systematic review and meta-analysis."
supports: SUPPORT
snippet: "In narcoleptic patients, modafinil in comparison with placebo is effective in the treatment of excessive daytime sleepiness, but not cataplexy."
explanation: Systematic review and meta-analysis of 9 RCTs confirms modafinil efficacy for excessive daytime sleepiness.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: modafinil
term:
id: CHEBI:31859
label: modafinil
- name: Pitolisant
description: Histamine H3 receptor antagonist, promotes wakefulness.
evidence:
- reference: PMID:34935103
reference_title: "Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials."
supports: SUPPORT
snippet: "The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy."
explanation: Analysis of randomized placebo-controlled trials demonstrates large effect sizes for pitolisant.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: pitolisant
term:
id: CHEBI:134709
label: pitolisant
- name: Solriamfetol
description: Dopamine/norepinephrine reuptake inhibitor for sleepiness.
evidence:
- reference: PMID:30694576
reference_title: "A randomized study of solriamfetol for excessive sleepiness in narcolepsy."
supports: SUPPORT
snippet: "Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy."
explanation: Phase 3 RCT demonstrated significant improvements in MWT and ESS scores versus placebo.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: solriamfetol
term:
id: NCIT:C152389
label: Solriamfetol
- name: Orexin Receptor 2 Agonists
description: >
Investigational mechanism-based therapy intended to replace deficient orexin
signaling in narcolepsy type 1 and consolidate wakefulness.
notes: TAK-861/oveporexton remains investigational in this entry; evidence includes model-organism and early clinical literature surfaced by deep research.
evidence:
- reference: DOI:10.1038/s41598-024-70594-1
reference_title: TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >
Similar to TAK-994, TAK-861 substantially ameliorates wakefulness
fragmentation and cataplexy-like episodes in orexin/ataxin-3 and
orexin-tTA;TetO DTA mice (NT1 mouse models).
explanation: >
The deep-research report identified OX2R agonists as mechanism-based
emerging therapy; this preclinical evidence supports biological rationale
while not yet establishing approved human treatment.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Amphetamines
description: Traditional stimulants (amphetamine, methylphenidate).
evidence:
- reference: PMID:18830438
reference_title: "Narcolepsy: current treatment options and future approaches."
supports: SUPPORT
snippet: "Modafinil has replaced methylphenidate and amphetamine as the first-line treatment of excessive daytime sleepiness (EDS) and sleep attacks"
explanation: Confirms amphetamines were traditional first-line treatments for EDS before modafinil.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Antidepressants
description: SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).
evidence:
- reference: PMID:30837110
reference_title: "Antidepressants for the treatment of narcolepsy: A prospective study of 148 patients in northern China."
supports: SUPPORT
snippet: "Venlafaxine demonstrated significantly greater improvements in MSL in the MWT (p < 0.01)."
explanation: Prospective study of 148 patients showed significant improvement in cataplexy and sleepiness with antidepressants.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
- name: Scheduled Naps
description: Short planned naps can improve alertness.
evidence:
- reference: PMID:18830438
reference_title: "Narcolepsy: current treatment options and future approaches."
supports: SUPPORT
snippet: "The management of narcolepsy is presently at a turning point."
explanation: Review discusses comprehensive narcolepsy management including behavioral approaches like scheduled naps.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: behavioral counseling
term:
id: NCIT:C181743
label: Behavioral Counseling
classifications:
harrisons_chapter:
- classification_value: NEUROLOGIC
datasets:
- accession: geo:GSE240851
title: The Transcriptomic Profiling of Blood CD4 and CD8 T-cells in Narcolepsy Type I
description: Background Narcolepsy Type I (NT1) is a rare, life-long sleep disorder arising as a consequence of the extensive destruction of orexin-producing hypothalamic neurons. The mechanisms involved in the destruction of orexin neurons are not yet elucidated but the association of narcolepsy with environmental triggers and genetic susceptibility (strong association with the HLA, TCRs and other immunologically-relevant loci) implicates an immuno-pathological process.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: BULK_RNA_SEQ
sample_count: 260
publication: PMID:38077397
notes: Identified by GEO DataSets index search for Narcolepsy (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE21592
title: Genome-wide gene expression profiling of human narcolepsy
description: 'Study objectives: The objectives of this study was perform the global gene expression profiling aimed at identifying differentially expressed genes in the circulating lympho-monocytes of NRLCP patients affected by Narcolepsy with Cataplexy (NRLCP). Based on the tight association to the HLA-DQB1*0602 haplotype in caucasians, it could be hypotesized an immunological dysregulation underlying the pathogenesis of the disease. Design: 10 NRLCP patients with 10 healthy controls were compared. Total RNA isolated from blood specimens was analyzed using microarray technology followed by statistical data analysis to detect genome-wide differential gene expression between patients and controls.'
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: MICROARRAY
sample_count: 20
publication: PMID:22783726
notes: Identified by GEO DataSets index search for Narcolepsy (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE247134
title: Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy
description: Narcolepsy is a rare cause of excessive daytime sleepiness and may be associated or not with cataplexy, i.e. sudden muscle weakness. These forms are designated NAR-type 1 (NT1) and -type 2 (NT2), respectively. Notable characteristics of narcolepsy are that most patients carry the HLA-DQB1*06:02 allele and NT1-patients have highly decreased levels hypocretin-1 (synonym orexin-A) in the cerebrospinal fluid (CSF). The pathogenesis of narcolepsy is still enigmatic but the strung HLA-bias and increased frequencies of CD4+ T cells reactive to hypocretin in the peripheral blood suggest autoimmune processes in the hypothalamus.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: SINGLE_CELL_RNA_SEQ
sample_count: 48
notes: Identified by GEO DataSets index search for Narcolepsy (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001004886
title: mRNA and T cell receptor sequencing of patients with Pandemrix-associated narcolepsy type 1
description: Increased risk of Narcolepsy type 1 (NT1) was reported among children and adolescents vaccinated with AS03-adjuvanted pandemic influenza A vaccine (H1N1; Pandemrix®). We hypothesized that viral T cell epitope(s) in Pandemrix mimicked self-epitope(s), and that recognition of these cross-reactive epitopes contributed to disease-specific autoimmunity. We demonstrate that pediatric, Pandemrix-associated NT1 patients had enhanced T-cell immunity against dominant T-cell epitopes of Pandemrix vaccine viral proteins neuraminidase (NA) and nucleoprotein (NP), and also responded against a self-epitope in brain-expressed protein-O-mannosyltransferase 1 (POMT1).
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Narcolepsy"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: massive:MSV000092401
title: LCMSMS Quantitation of HILIC Enriched N glycopeptides derived from low abundance serum glycoproteins in patients with Narcolepsy Type I
description: Glycoproteomics analysis is always challenging because of low abundance and complex site-specific heterogeneity. Glycoproteins are involved in various biological processes such as cell signaling, adhesion, and cell cell communication and may serve as potential biomarkers when analyzing different diseases. Here, we study glycoproteins in Narcolepsy Type I disease, a variant of narcolepsy characterized by cataplexy the sudden onset of muscle weakness usually caused by strong emotions. There is currently no cure for this life-altering disease.
notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Narcolepsy"). Retrieved 2026-08-02.
references:
- reference: DOI:10.1001/archneur.59.10.1553
title: The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias
supporting_text: The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias
- reference: DOI:10.1016/j.sleepx.2024.100122
title: 'RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates'
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: 'RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates'
supporting_text: 'RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates'
- reference: DOI:10.1038/s41598-024-70594-1
title: TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy.
supporting_text: Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy.
evidence:
- reference: DOI:10.1038/s41598-024-70594-1
reference_title: TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Narcolepsy type 1 (NT1) is associated with severe loss of orexin neurons and characterized by symptoms including excessive daytime sleepiness and cataplexy.
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.1056/nejmoa2405847
title: Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
supporting_text: Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1
- reference: DOI:10.1111/iji.12688
title: High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid.
supporting_text: Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid.
evidence:
- reference: DOI:10.1111/iji.12688
reference_title: High‐resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Narcolepsy is a sleep disorder caused by an apparent degeneration of orexin/hypocretin neurons in the lateral hypothalamic area and a subsequent decrease in orexin/hypocretin levels in the cerebrospinal fluid.
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.1111/jsr.14277
title: Narcolepsy and rapid eye movement sleep
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Since the first description of narcolepsy at the end of the 19th Century, great progress has been made.
supporting_text: Since the first description of narcolepsy at the end of the 19th Century, great progress has been made.
evidence:
- reference: DOI:10.1111/jsr.14277
reference_title: Narcolepsy and rapid eye movement sleep
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Since the first description of narcolepsy at the end of the 19th Century, great progress has been made.
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3389/fphar.2024.1415918
title: 'Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database'
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management.
supporting_text: Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management.
evidence:
- reference: DOI:10.3389/fphar.2024.1415918
reference_title: 'Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Narcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management.
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3389/fpsyt.2026.1799520
title: 'Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine'
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy.
supporting_text: Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy.
evidence:
- reference: DOI:10.3389/fpsyt.2026.1799520
reference_title: 'Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine'
supports: SUPPORT
evidence_source: OTHER
snippet: Narcolepsy can no longer be adequately conceptualized by excessive sleepiness and cataplexy.
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3390/ctn8030025
title: 'Pediatric Narcolepsy Type 1: A State-of-the-Art Review'
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence.
supporting_text: Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence.
evidence:
- reference: DOI:10.3390/ctn8030025
reference_title: 'Pediatric Narcolepsy Type 1: A State-of-the-Art Review'
supports: SUPPORT
evidence_source: OTHER
snippet: Narcolepsy is a chronic central disorder of hypersomnolence most frequently arising during childhood/adolescence.
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3390/ijms252211914
title: 'The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review'
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep.
supporting_text: Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep.
evidence:
- reference: DOI:10.3390/ijms252211914
reference_title: 'The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review'
supports: SUPPORT
evidence_source: OTHER
snippet: Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep.
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
- reference: DOI:10.3390/jcm14238444
title: A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1
found_in:
- Narcolepsy-deep-research-falcon.md
- Narcolepsy-deep-research-cyberian-codex.md
findings:
- statement: A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1
supporting_text: Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder characterized by core clinical manifestations such as excessive daytime sleepiness (EDS), cataplexy, sleep paralysis (SP), hypnagogic and hypnopompic hallucinations (HHs), and disrupted nocturnal sleep (DNS).
evidence:
- reference: DOI:10.3390/jcm14238444
reference_title: A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1
supports: SUPPORT
evidence_source: OTHER
snippet: Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder characterized by core clinical manifestations such as excessive daytime sleepiness (EDS), cataplexy, sleep paralysis (SP), hypnagogic and hypnopompic hallucinations (HHs), and disrupted nocturnal sleep (DNS).
explanation: Deep research cited this publication as relevant literature for Narcolepsy.
Narcolepsy is a chronic central disorder of hypersomnolence characterized by excessive daytime sleepiness (EDS) with rapid-eye-movement (REM) sleep dysregulation, and is currently classified into narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). NT1 is strongly linked to orexin/hypocretin deficiency and commonly includes cataplexy; NT2 lacks cataplexy and typically does not show orexin deficiency, with etiology less well established. (biscarini2025narcolepsyandrapid pages 1-2, xu2025acomprehensivereview pages 1-2)
The retrieved full texts did not contain authoritative identifier mappings (ICD-10/ICD-11, MeSH, OMIM, Orphanet, MONDO). Therefore, these identifiers cannot be populated from the current evidence set and should be curated from dedicated terminologies (e.g., ICD/MeSH/MONDO/Orphanet) outside this tool run.
This report integrates aggregated disease-level resources (reviews, cohorts, pharmacovigilance databases) and some patient-level evidence (e.g., clinical diagnostic criteria tables compiled in reviews). (baldini2024pediatricnarcolepsytype pages 1-2, zhou2024evaluationofpitolisant pages 1-2)
Narcolepsy is now commonly conceptualized as a disorder of sleep–wake and REM-state boundary control. A modern “systems” view emphasizes multisystem consequences of hypothalamic orexin dysfunction rather than only the classic symptom pentad. (ariascarrion2026narcolepsyasan pages 2-3)
Direct abstract-supported definition/overview: A review of REM sleep and narcolepsy summarizes that narcolepsy is divided into NT1 and NT2, with key criteria relying on SOREMPs captured on polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT), and that NT1 mechanisms are partly elucidated through HLA association and orexin/hypocretin deficiency. (biscarini2025narcolepsyandrapid pages 1-2)
NT1 is linked to selective loss/dysfunction of hypothalamic orexin-producing neurons and is increasingly supported as an immune-mediated disease in genetically predisposed individuals. (xu2025acomprehensivereview pages 1-2, ariascarrion2026narcolepsyasan pages 5-6)
A narrative review of T-cell involvement states that NT1 can be understood via interplay of genetic predisposition (notably HLA-DQB1*06:02), environmental triggers (e.g., H1N1 infection/vaccination), and immune mechanisms leading to hypocretin neuronal loss. (xu2024theroleof pages 1-2)
NT2 typically lacks cataplexy and orexin deficiency; its causes remain less well defined. However, subgroups with intermediate orexin levels may overlap immunogenetically with NT1. (biscarini2025narcolepsyandrapid pages 1-2, hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 3-3)
The retrieved evidence did not provide clearly defined protective genetic variants or modifiable environmental protective factors for narcolepsy in a way that can be summarized with specificity.
The most consistent G×E framework in the retrieved literature is HLA-driven antigen presentation + environmental priming (H1N1 infection/vaccination) leading to T-cell activation and ultimately selective injury of orexin neurons. (xu2024theroleof pages 1-2, xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6)
Classic symptom cluster often includes EDS, cataplexy (NT1), disrupted nighttime sleep, sleep paralysis, and hypnagogic/hypnopompic hallucinations. Pediatric NT1 reviews explicitly enumerate these as core symptoms. (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 2-4)
Pediatric-specific presentation nuances * EDS may be “masked” by hyperactivity/irritability and may be misdiagnosed as ADHD. (baldini2024pediatricnarcolepsytype pages 2-4) * Cataplexy in children may have atypical semiology (“cataplectic facies” with facial hypotonia/ptosis and mixed hyperactive movements). (baldini2024pediatricnarcolepsytype pages 2-4)
A pediatric state-of-the-art review emphasizes that NT1 impairs children’s quality of life and supports early diagnosis and multidisciplinary management, including behavioral and psychosocial interventions. (baldini2024pediatricnarcolepsytype pages 1-2)
The retrieved sources support the following phenotype constructs; HPO codes should be verified in an ontology browser: * Excessive daytime sleepiness (EDS) (baldini2024pediatricnarcolepsytype pages 2-4) * Cataplexy (baldini2024pediatricnarcolepsytype pages 2-4) * Sleep paralysis (baldini2024pediatricnarcolepsytype pages 1-2) * Hypnagogic/hypnopompic hallucinations (baldini2024pediatricnarcolepsytype pages 1-2) * Fragmented sleep / disturbed nighttime sleep (baldini2024pediatricnarcolepsytype pages 2-4) * REM sleep behavior disorder (baldini2024pediatricnarcolepsytype pages 2-4) * Rapid weight gain/obesity (pediatric onset-associated) (biscarini2025narcolepsyandrapid pages 5-6) * Precocious puberty (pediatric onset-associated) (biscarini2025narcolepsyandrapid pages 5-6)
For idiopathic NT1, the dominant genetic signal is polygenic (not a single Mendelian “causal gene”). However, a REM-sleep/narcolepsy review notes that a canine model identified mutations in the orexin receptor 2 pathway (historically important to orexin biology). (biscarini2025narcolepsyandrapid pages 1-2)
A landmark diagnostic study defined CSF hypocretin-1 ≤110 pg/mL as a best-performing diagnostic cutoff (with >200 pg/mL considered normal), and in “typical cataplexy” reported sensitivity 87% and specificity 99%. (mignot2002theroleof pages 5-6, mignot2002theroleof pages 8-9)
A 2024 high-resolution HLA/autoantibody study found no difference in anti-HCRTR2 autoantibody levels across NT1, NT2, idiopathic hypersomnia, and general population controls (p=.8524), suggesting hypocretin receptor 2 is unlikely to be a major autoimmune target in these cohorts. (hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 6-6)
The retrieved evidence notes that epigenetic alterations have been reported (e.g., within immune loci), but does not provide specific methylation loci or standardized effect sizes in the excerpts available here. (xu2024theroleof pages 14-15, ariascarrion2026narcolepsyasan pages 7-8)
1) Genetic susceptibility: strong HLA class II association (e.g., DQB106:02) and additional immune/TCR loci (xu2024theroleof pages 2-3, hamdan2024high‐resolutionhlasequencing pages 4-5) 2) Environmental priming: H1N1 influenza infection and/or Pandemrix vaccination in specific outbreaks (xu2024theroleof pages 1-2, xu2024theroleof pages 3-5) 3) Immune activation and autoimmunity: evidence supports autoreactive CD4+ and CD8+ T cells targeting orexin-related antigens; molecular mimicry is plausible but not fully resolved across studies (xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6) 4) Selective orexin neuron loss/dysfunction: substantial neuron loss has been estimated (75–95% loss in NT1 described in a systems review) (ariascarrion2026narcolepsyasan pages 5-6) 5) Network-level consequences*: destabilized wake maintenance and REM boundary control producing EDS, SOREMPs, cataplexy, hallucinations, and sleep paralysis (xu2025acomprehensivereview pages 9-11, biscarini2025narcolepsyandrapid pages 1-2)
Evidence supports immune effector involvement and hypothalamic neuron injury: * CL terms (suggested): CD4-positive T cell; CD8-positive T cell; hypothalamic orexin neuron; histaminergic neuron (TMN) (TAK-861 depolarizes TMN histaminergic neurons via OX2R) (xu2024theroleof pages 7-8, mitsukawa2024tak861apotent pages 2-3) * GO biological processes (suggested): antigen processing and presentation (MHC class II); T cell activation; IFN-γ–mediated signaling and MHC I upregulation; regulation of sleep–wake cycle; regulation of REM sleep (xu2024theroleof pages 7-8, biscarini2025narcolepsyandrapid pages 1-2)
The evidence supports narcolepsy (especially NT1) as multifactorial/polygenic with strong HLA association rather than Mendelian inheritance. (xu2024theroleof pages 2-3, xu2024theroleof pages 3-5)
Pediatric narcolepsy is emphasized as frequently beginning in childhood/adolescence, and pediatric phenotype has distinctive features (e.g., weight gain and atypical cataplexy semiology). (biscarini2025narcolepsyandrapid pages 5-6, baldini2024pediatricnarcolepsytype pages 2-4)
The pediatric NT1 review reproduces ICSD-3-TR (2023) diagnostic criteria for NT1 and NT2, including EDS duration, MSLT requirements (mean sleep latency ≤8 min and ≥2 SOREMPs), cataplexy status, and CSF hypocretin thresholds, and illustrates the ICSD-3-TR change that allows nocturnal PSG SOREMP + cataplexy to suffice for NT1 diagnosis even if MSLT is not definitive. (baldini2024pediatricnarcolepsytype media 3ad4bd72, baldini2024pediatricnarcolepsytype pages 8-9)
Diagnostic workup emphasizes excluding insufficient sleep and circadian disorders (actigraphy 7–10 days), and distinguishing NT2 from idiopathic hypersomnia (IH) via SOREMP patterns and/or total sleep time. (baldini2024pediatricnarcolepsytype pages 9-11)
A synthesis review rates modafinil/armodafinil, solriamfetol, pitolisant, and sodium oxybate formulations as high-certainty, strong-recommendation symptomatic treatments. (ariascarrion2026narcolepsyasan pages 21-22)
Pediatric regulatory status and practice A pediatric NT1 review notes: * No approvals under age 6. * Sodium oxybate is approved by FDA and EMA for ages ≥7. * EMA approved pitolisant in 2023 for patients >6 years with or without cataplexy. (baldini2024pediatricnarcolepsytype pages 11-13)
RESTORE (2024) evaluated switching from twice-nightly immediate-release oxybate to once-nightly extended-release sodium oxybate: * 93.9% (92/98) preferred once-nightly dosing. * Prior to switching, 69.2% had missed the second dose at least once; nocturnal mobility after the second dose was common, with reported falls and injuries. * After switching, 91.2% felt better able to follow the recommended dosing schedule. These data emphasize adherence/safety burdens of middle-of-the-night redosing and a real-world rationale for simplified regimens. (roy2024restoreoncenightlyoxybate pages 1-2, roy2024restoreoncenightlyoxybate pages 2-3)
A major 2023–2024 development area is small-molecule OX2R agonists designed to replace deficient orexin signaling.
Preclinical evidence (2024): TAK-861 (oveporexton) A 2024 Scientific Reports study characterized TAK-861 as an oral OX2R-selective agonist with OX2R EC50 2.5 nM and ~3,000-fold selectivity over OX1R. It promoted wakefulness in mice and monkeys (minimum effective dose 1 mg/kg) and improved narcolepsy-like phenotypes in NT1 mouse models (orexin/ataxin-3 and orexin-tTA;TetO DTA), including reduced wake fragmentation and reduced cataplexy-like episodes. (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 3-4, mitsukawa2024tak861apotent pages 2-3, mitsukawa2024tak861apotent pages 10-11)
Clinical development (trial registry; real-world implementation horizon) Multiple trials are registered for orexin agonists including TAK-861 and danavorexton (TAK-925). Examples include completed and recruiting studies spanning Phase 1–3 (e.g., NCT05687903 Phase 2; Phase 3 trials listed for TAK-861; TAK-925 Phase 1 programs). (xu2025acomprehensivereview pages 9-11)
A 2024 FAERS analysis (2019–2023) identified signal counts: 50 signals/762 cases for pitolisant, 640/46,962 for sodium oxybate, 40/1,228 for solriamfetol, and 72/632 for modafinil. Psychiatric and nervous system disorders predominated; sodium oxybate showed strong respiratory-related signals (e.g., sleep apnea syndrome n=1326 with high disproportionality metrics) and hypertension signals. These are signal-detection outputs without denominators and cannot be interpreted as incidence rates, but they inform monitoring priorities. (zhou2024evaluationofpitolisant pages 1-2, zhou2024evaluationofpitolisant pages 8-9)
Based on interventions discussed: * Pharmacotherapy for hypersomnolence / wake promotion (modafinil/armodafinil/solriamfetol/pitolisant) (ariascarrion2026narcolepsyasan pages 21-22) * Oxybate therapy (sodium oxybate; low-sodium oxybate; once-nightly formulations) (roy2024restoreoncenightlyoxybate pages 1-2, baldini2024pediatricnarcolepsytype pages 11-13) * Orexin receptor agonist therapy (OX2R agonists) (mitsukawa2024tak861apotent pages 1-2) * Behavioral sleep intervention (planned naps, sleep hygiene, school programs) (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 11-13)
No established primary prevention strategy exists for idiopathic NT1/NT2.
Evidence supports early diagnosis and multidisciplinary management in pediatrics to reduce educational/psychosocial impact, plus careful monitoring for comorbidities (metabolic/endocrine, psychiatric) and medication adverse effects. (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 14-15)
Pandemrix-associated risk signals are part of the etiologic history in some countries, but causality and generalization to modern vaccines are complex; a recent immunology-focused narrative emphasizes that mechanistic mimicry is plausible but incompletely resolved and that findings vary across studies. (xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6)
The orexin system has strong translational animal models. A 2024 preclinical therapeutic paper uses: * orexin/ataxin-3 mice (orexin neuron degeneration model) * orexin-tTA;TetO DTA mice (conditional orexin neuron ablation) These models support evaluation of orexin-pathway therapeutics for wake consolidation and cataplexy-like behaviors. (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 10-11)
The retrieved evidence emphasizes that models typically capture fragments of the human phenotype (e.g., cataplexy-like episodes, fragmentation) and are most directly aligned with NT1 biology rather than NT2 heterogeneity. (mitsukawa2024tak861apotent pages 1-2, biscarini2025narcolepsyandrapid pages 1-2)
The following table consolidates the most actionable recent and foundational evidence captured in this tool run.
| Topic | Key data/statistics | Source (first author, year, journal) | URL | Notes |
|---|---|---|---|---|
| ICSD-3-TR diagnostic criteria | 2023 ICSD-3-TR allows NT1 diagnosis when cataplexy is present together with a nocturnal PSG SOREMP, even without relying on MSLT/hypocretin confirmation; standard criteria still include mean sleep latency ≤8 min and ≥2 SOREMPs, or CSF hypocretin-1 ≤110 pg/mL / <1/3 of controls (baldini2024pediatricnarcolepsytype pages 8-9, baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype media 3ad4bd72) | Baldini, 2024, Clinical and Translational Neuroscience | https://doi.org/10.3390/ctn8030025 | Useful update for diagnostic workflows, especially pediatrics and difficult MSLT cases |
| Pediatric phenotypes | Disturbed nighttime sleep (DNS) affects 53–78% of pediatric NT1; REM sleep behavior disorder (RBD) is reported in up to 60% and may be early/severe in children (baldini2024pediatricnarcolepsytype pages 2-4) | Baldini, 2024, Clinical and Translational Neuroscience | https://doi.org/10.3390/ctn8030025 | Pediatric presentation can include atypical cataplexy and ADHD-like behaviors |
| CSF hypocretin biomarker | CSF hypocretin-1 cutoff ≤110 pg/mL (with >200 pg/mL considered normal); in typical cataplexy, sensitivity 87% and specificity 99%, PPV 96%, NPV 96% (mignot2002theroleof pages 5-6, mignot2002theroleof pages 8-9) | Mignot, 2002, Archives of Neurology | https://doi.org/10.1001/archneur.59.10.1553 | Strongest biomarker for NT1; interpretation needed in secondary hypothalamic disease |
| HLA associations | NT1-associated haplotype DRB501:01:01-DRB115:01:01-DQA101:02:01-DQB106:02:01: OR 7.01 (95% CI 3.97–12.37); genotype OR 9.15. Multilocus genotype including DRB401:03:01/DRB104:01:01/DQA103:02 or 03:03:01/DQB1*03:01:01: OR 23.61 (95% CI 4.48–110.76). Anti-HCRTR2 autoantibodies were not different across groups (p=.8524) (hamdan2024high‐resolutionhlasequencing pages 4-5, hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 6-6) | Hamdan, 2024, International Journal of Immunogenetics | https://doi.org/10.1111/iji.12688 | Supports strong HLA-driven susceptibility; no support here for HCRTR2 autoantibody pathogenicity |
| T-cell autoimmunity and risk loci | NT1 is framed as predominantly T-cell–mediated autoimmunity; HLA-DQB1*06:02 present in ~98% of NT1 with cataplexy vs ~25% of general population; reported risk loci include TRA, CTSH rs34593439, PPAN rs1551570, P2RY11 rs2305795, IL10RB/rs2834188, CPT1B rs5770917; H1N1/Pandemrix implicated as environmental triggers (xu2024theroleof pages 2-3, xu2024theroleof pages 3-5, xu2024theroleof pages 7-8, xu2024theroleof pages 1-2) | Xu, 2024, International Journal of Molecular Sciences | https://doi.org/10.3390/ijms252211914 | Molecular mimicry is plausible but incompletely resolved |
| TAK-861 preclinical evidence | TAK-861 (oveporexton) activated OX2R with EC50 2.5 nM and ~3,000-fold selectivity over OX1R; improved wakefulness and reduced cataplexy-like episodes in orexin/ataxin-3 and orexin-tTA;TetO DTA mouse models; wake-promoting MED 1 mg/kg in mice and monkeys (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 3-4, mitsukawa2024tak861apotent pages 2-3, mitsukawa2024tak861apotent pages 10-11) | Mitsukawa, 2024, Scientific Reports | https://doi.org/10.1038/s41598-024-70594-1 | Mechanism-based therapy aimed at replacing lost orexin signaling |
| Oveporexton phase 2 outcomes | In NT1, 8-week trial: mean MWT change +12.5 to +25.4 min vs -1.2 placebo; ESS change -8.9 to -13.8 vs -2.5 placebo; weekly cataplexy at week 8: 2.48–5.89 vs 8.76 placebo depending on dose; common AEs insomnia 48%, urinary urgency 33%, urinary frequency 32%; no hepatotoxicity reported (abstract evidence from retrieved paper search) | Dauvilliers, 2025, New England Journal of Medicine | https://doi.org/10.1056/NEJMoa2405847 | Phase 2 TAK-861/oveporexton trial, NCT05687903 |
| Once-nightly oxybate preference | In RESTORE, 92/98 (93.9%) preferred once-nightly sodium oxybate after switching; 69.2% had missed the second IR oxybate dose at least once; 91.2% felt better able to follow dosing schedule; 92.6% would recommend ON-SXB (roy2024restoreoncenightlyoxybate pages 1-2, roy2024restoreoncenightlyoxybate pages 2-3, roy2024restoreoncenightlyoxybate pages 4-5) | Roy, 2024, Sleep Medicine: X | https://doi.org/10.1016/j.sleepx.2024.100122 | Highlights real-world burden of middle-of-the-night redosing |
| Real-world pharmacovigilance | FAERS 2019–2023 identified 50 signals/762 cases for pitolisant, 640/46,962 for sodium oxybate, 40/1,228 for solriamfetol, and 72/632 for modafinil; psychiatric and nervous system ADEs predominated. Sodium oxybate had notable signals for sleep apnea syndrome (n=1326), respiratory depression (n=104), apnea (n=95), and hypertension (n=1081) (zhou2024evaluationofpitolisant pages 1-2, zhou2024evaluationofpitolisant pages 3-4, zhou2024evaluationofpitolisant pages 8-9) | Zhou, 2024, Frontiers in Pharmacology | https://doi.org/10.3389/fphar.2024.1415918 | FAERS signals are hypothesis-generating, not incidence estimates |
| Epidemiology snapshot | Recent review summarized prevalence around 37.7/100,000 in the U.S. and incidence ~2.6/100,000 person-years; Japan claims data ~37.5/100,000 prevalence and 5.1/100,000 person-years incidence, with strong geographic variability (ariascarrion2026narcolepsyasan pages 3-4) | Arias-Carrión, 2026, Frontiers in Psychiatry | https://doi.org/10.3389/fpsyt.2026.1799520 | Useful contextual benchmark; not a primary epidemiology study |
Table: This table compiles high-yield recent and foundational evidence for narcolepsy across diagnosis, biomarkers, immunogenetics, therapeutics, and real-world safety. It is useful as a quick-reference summary for a disease knowledge base entry.
Primary sources used (examples; see citations inline): * Baldini V. et al. Pediatric Narcolepsy Type 1: A State-of-the-Art Review. Clinical and Translational Neuroscience. 2024-06. https://doi.org/10.3390/ctn8030025 (baldini2024pediatricnarcolepsytype pages 1-2) * Xu W. et al. The Role of T Cells in the Pathogenesis of Narcolepsy Type 1. Int J Mol Sci. 2024-11. https://doi.org/10.3390/ijms252211914 (xu2024theroleof pages 1-2) * Hamdan S. et al. High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies. Int J Immunogenet. 2024-06. https://doi.org/10.1111/iji.12688 (hamdan2024high‐resolutionhlasequencing pages 1-2) * Mitsukawa K. et al. TAK-861 OX2R agonist preclinical study. Scientific Reports. 2024-09. https://doi.org/10.1038/s41598-024-70594-1 (mitsukawa2024tak861apotent pages 1-2) * Roy A. et al. RESTORE once-nightly oxybate preference. Sleep Medicine: X. 2024-12. https://doi.org/10.1016/j.sleepx.2024.100122 (roy2024restoreoncenightlyoxybate pages 1-2) * Zhou X. et al. FAERS pharmacovigilance analysis. Front Pharmacol. 2024-11. https://doi.org/10.3389/fphar.2024.1415918 (zhou2024evaluationofpitolisant pages 1-2) * Mignot E. et al. CSF hypocretin measurement diagnostic performance. Archives of Neurology. 2002-10. https://doi.org/10.1001/archneur.59.10.1553 (mignot2002theroleof pages 5-6)
References
(biscarini2025narcolepsyandrapid pages 1-2): Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, and Yves Dauvilliers. Narcolepsy and rapid eye movement sleep. Journal of Sleep Research, Jul 2025. URL: https://doi.org/10.1111/jsr.14277, doi:10.1111/jsr.14277. This article has 14 citations and is from a peer-reviewed journal.
(xu2025acomprehensivereview pages 1-2): Qinglin Xu, Yigang Chen, Tiantian Wang, Qiongbin Zhu, Jiahui Xu, and Lisan Zhang. A comprehensive review of current and emerging treatments for narcolepsy type 1. Journal of Clinical Medicine, 14:8444, Nov 2025. URL: https://doi.org/10.3390/jcm14238444, doi:10.3390/jcm14238444. This article has 1 citations.
(ariascarrion2026narcolepsyasan pages 3-4): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(mignot2002theroleof pages 5-6): Emmanuel Mignot, Gert Jan Lammers, Beth Ripley, Michele Okun, Sonia Nevsimalova, Sebastiaan Overeem, Jitka Vankova, Jed Black, John Harsh, Claudio Bassetti, Harald Schrader, and Seiji Nishino. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of neurology, 59 10:1553-62, Oct 2002. URL: https://doi.org/10.1001/archneur.59.10.1553, doi:10.1001/archneur.59.10.1553. This article has 1400 citations.
(baldini2024pediatricnarcolepsytype pages 1-2): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(zhou2024evaluationofpitolisant pages 1-2): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.
(ariascarrion2026narcolepsyasan pages 2-3): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(ariascarrion2026narcolepsyasan pages 5-6): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(xu2024theroleof pages 1-2): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(hamdan2024high‐resolutionhlasequencing pages 1-2): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(hamdan2024high‐resolutionhlasequencing pages 3-3): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(hamdan2024high‐resolutionhlasequencing pages 4-5): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(xu2024theroleof pages 2-3): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(xu2024theroleof pages 3-5): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(xu2024theroleof pages 7-8): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 2-4): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(biscarini2025narcolepsyandrapid pages 5-6): Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, and Yves Dauvilliers. Narcolepsy and rapid eye movement sleep. Journal of Sleep Research, Jul 2025. URL: https://doi.org/10.1111/jsr.14277, doi:10.1111/jsr.14277. This article has 14 citations and is from a peer-reviewed journal.
(mignot2002theroleof pages 8-9): Emmanuel Mignot, Gert Jan Lammers, Beth Ripley, Michele Okun, Sonia Nevsimalova, Sebastiaan Overeem, Jitka Vankova, Jed Black, John Harsh, Claudio Bassetti, Harald Schrader, and Seiji Nishino. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of neurology, 59 10:1553-62, Oct 2002. URL: https://doi.org/10.1001/archneur.59.10.1553, doi:10.1001/archneur.59.10.1553. This article has 1400 citations.
(hamdan2024high‐resolutionhlasequencing pages 6-6): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.
(xu2024theroleof pages 14-15): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.
(ariascarrion2026narcolepsyasan pages 7-8): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(xu2025acomprehensivereview pages 9-11): Qinglin Xu, Yigang Chen, Tiantian Wang, Qiongbin Zhu, Jiahui Xu, and Lisan Zhang. A comprehensive review of current and emerging treatments for narcolepsy type 1. Journal of Clinical Medicine, 14:8444, Nov 2025. URL: https://doi.org/10.3390/jcm14238444, doi:10.3390/jcm14238444. This article has 1 citations.
(mitsukawa2024tak861apotent pages 2-3): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(baldini2024pediatricnarcolepsytype media 3ad4bd72): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 8-9): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(ariascarrion2026narcolepsyasan pages 21-22): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.
(baldini2024pediatricnarcolepsytype pages 9-11): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 11-13): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(roy2024restoreoncenightlyoxybate pages 1-2): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.
(roy2024restoreoncenightlyoxybate pages 2-3): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.
(mitsukawa2024tak861apotent pages 1-2): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(mitsukawa2024tak861apotent pages 3-4): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(mitsukawa2024tak861apotent pages 10-11): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.
(zhou2024evaluationofpitolisant pages 8-9): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.
(baldini2024pediatricnarcolepsytype pages 14-15): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.
(roy2024restoreoncenightlyoxybate pages 4-5): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.
(zhou2024evaluationofpitolisant pages 3-4): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.